Generic Injectables Market Research Report, by Product Type (Monoclonal antibodies, Cytokines, Insulin, Vaccines), Container (Vials, Ampoules, Premix, Prefilled syringes), Application (Oncology, Anaesthesia, Anti-infectives, Cardiovascular), Distribution Channel (Hospital pharmacy, Retail pharmacy, Drug stores, Online stores) – Forecast Till 2027
ID: MRFR/HC/6043-HCR | February 2021 | Region: Global | 100 pages
Generic Injectables Market Scenario
The generic injectables market is projected to grow significantly over the forecast period. It is estimated that the market is expected to register a CAGR of 13% during the forecast period of 2018–2023.
Generic injectable is referred to as biologics that are used for the treatment of various disease and has same drug/ active ingredients as that of its respective branded versions. However, the inactive contents of the drugs can be varied. The increasing prevalence of chronic and infectious disease along with the advancement in research and academic initiatives by the private and governmental sector is expected to drive the market growth.
For instance, as per the World Health Organization (WHO) 2015, over 38 million death occur globally due to non- communicable chronic diseases annually, which is propelling demand for development of low-cost generic vaccines. Moreover, nearly 86% of infants are vaccinated the rest remain unvaccinated leading to a death toll of about 2-3 million infants annually. Shortage of branded sterile injectable has further led to the adoption of generic injectable which in-turn is expected to restrain the generic injectables market growth.
Segmentation
The generic injectables market is segmented on the basis of product type, container, application, distribution channel, and end user.
The market, by product type is categorised into monoclonal antibodies, cytokines, insulin, vaccines, and others.
On the basis of container, the market is segmented into vials, ampoules, premix, and prefilled syringes.
Based on application, the generic injectables market is segmented oncology, anaesthesia, anti-infectives, parenteral nutrition, cardiovascular, and others.
The market, by distribution channel is categorised into hospital pharmacy, retail pharmacy, drug stores, and online prescription stores.
On the basis of region, the generic injectables market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The generic injectables market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Global Generic injectables Market Share (%), by Region, 2017
Sources: Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, National Institutes of Health
It is projected that the Americas dominated the generic injectables market owing to the growth of the market in the North American region. This is largely attributed to the factors such as an increase in drug shortages, especially in the US, along with patent expiry of a number of blockbuster drugs. Even though the generic injectable industry has operations across the globe, majority of largest manufacturers produce a large volume of generic injectable in the U.S. Moreover, in the U.S. over 70% of hospital patients receive generic injectable drugs, which is further pushing the demand for generic injectable in North America.
Europe is currently holding a considerable amount of market share in the generic injectables market owing to the advantages offered by generic injectables, governments in various countries are supporting their manufacture. For instance, in June 2017, Baxter signed an agreement with Dorizoe for life sciences company manufacturing generic sterile injectable. This alliance is anticipated to develop more than 20 generic injectable products including cardiovascular and oncolytic medicines.
Asia-Pacific was projected to be the fastest growing region for the generic injectables market. This owes to the infrastructural development and increase in outsourcing of research activities to the contract research organizations (CROs) at relatively low cost in this region. For example, the Sun Pharma’s acquisition of Pharmalucence in 2014 that resulted in benchmarking sales of generic sterile injectable.
The Middle East and Africa holds the least share in the generic injectables market due to the presence of economically diverse countries, and less initiatives taken by the government.
Market of Generic Injectables, by Product type
- Monoclonal antibodies
- Cytokines
- Insulin
- Vaccines
- Others
Market of Generic Injectables, by Container
- Vials
- Ampoules
- Premix
- Prefilled syringes
Market of Generic Injectables, by Application
- Oncology
- Anaesthesia
- Anti-infectives
- Parenteral nutrition
- Cardiovascular
- Others
Market of Generic Injectables, by Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Drug stores
- Online prescription stores
- Others
Market of Generic Injectables, by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- The Middle East & Africa
- Middle East
- Africa
Market of Generic Injectables, Key Players
- Novartis AG (Sandoz International GmbH)
- Baxter
- Fresenius SE & Co. KGaA
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals plc
- Sanofi
- Biocon
- Reddy’s Laboratories
- Aurobindo Pharma
- Zydus Cadila
- GlaxoSmithKline plc
- AstraZeneca plc.
Intended Audience
- Pharmaceutical & Biopharmaceutical companies
- Biotechnological companies
- Government institutions
- Research and Development (R&D) companies
- Medical research laboratories
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2027: Significant Value |
| CAGR | 13% (2018-2023) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Container, Application and Distribution Channel |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co. KGaA, Mylan N.V., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals plc, Sanofi, Biocon, Reddy’s Laboratories, Aurobindo Pharma, Zydus Cadila, GlaxoSmithKline plc, AstraZeneca plc. |
| Key Market Opportunities | joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments |
| Key Market Drivers | Increasing prevalence of chronic and infectious disease along with the advancement in research and academic initiatives |
Frequently Asked Questions (FAQ) :
The global generic injectables market is expected to exhibit a strong 13% CAGR over the forecast period from 2018 to 2023.
The increasing prevalence of chronic and infectious diseases is driving the demand for effective generic injectables.
Key types of generic injectables include monoclonal antibodies, cytokines, insulin, vaccines, and others.
The Americas is likely to dominate the global generic injectables market.
Leading players in the generic injectables market include Novartis, Baxter, Sanofi, Biocon, and Zydus Cadila, among others.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.